Insider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells $85,526.15 in Stock

Aileron Therapeutics, Inc. (NASDAQ:ALRN) major shareholder Of Texas/Texas Am I. University sold 20,315 shares of Aileron Therapeutics stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $4.21, for a total value of $85,526.15. Following the sale, the insider now directly owns 1,779,306 shares of the company’s stock, valued at approximately $7,490,878.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Aileron Therapeutics Stock Performance

ALRN opened at $3.76 on Friday. Aileron Therapeutics, Inc. has a fifty-two week low of $1.01 and a fifty-two week high of $7.42. The company has a market capitalization of $63.42 million, a P/E ratio of -1.11 and a beta of 2.32. The stock has a fifty day moving average of $5.38 and a 200-day moving average of $3.84.

Aileron Therapeutics (NASDAQ:ALRN) last posted its earnings results on Monday, April 15th. The company reported ($1.54) earnings per share for the quarter. On average, equities research analysts predict that Aileron Therapeutics, Inc. will post -0.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aileron Therapeutics stock. Texas Capital Bank Wealth Management Services Inc purchased a new position in Aileron Therapeutics, Inc. (NASDAQ:ALRN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,773 shares of the company’s stock, valued at approximately $48,000. Texas Capital Bank Wealth Management Services Inc owned 0.32% of Aileron Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 90.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH lifted their target price on Aileron Therapeutics from $9.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, April 18th.

About Aileron Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.